Perjeta 420 MG/14 ML vial 14ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWH0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,651
Award facts
- Contract value 100% obligated
- $4,650.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,650.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, issued on December 17, 2025, with an ultimate completion date of January 9, 2026, utilizes firm fixed-price pricing with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense military healthcare facilities worldwide.
The PPV-G GEN V contract represents DMS Pharmaceutical Group's qualification as a regional prime vendor contractor, positioning the company to supply an extensive range of pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and medical consumables to support recurring medical supply needs across the global military healthcare system. The underlying IDC, awarded on November 13, 2025, carries a $500 million ceiling and extends through December 31, 2036, structured with a 30-month base period and three 30-month option periods. Through this vehicle, DLA can issue firm fixed-price delivery orders for specialized pharmaceutical requirements, with Perjeta—a biologic oncology treatment—exemplifying the specialized therapeutic categories the company is authorized to supply to military medical facilities.
Quick answers
Who was awarded contract SPE2DR26FQWH0?
SPE2DR26FQWH0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FQWH0 worth?
The government has obligated $4,651 on SPE2DR26FQWH0.
Is contract SPE2DR26FQWH0 an order under another contract?
Yes. SPE2DR26FQWH0 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWH0 competed?
The extent of competition for SPE2DR26FQWH0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award